Influence of analgesic active 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1- yl]-dihydrofuran-2-one on the antioxidant status, glucose utilization and lipid accumulation in some in vitro and ex vivo assays

Toxicology Mechanisms and Methods

Volumn 24, Issue 3, 2014, Pages 204-211

  Sałat, Kinga ^a   Głuch Lutwin, Monika ^b   Nawieśniak, Barbara ^b   Gawlik, Katarzyna ^b   Pawlica Gosiewska, Dorota ^b   Witalis, Jadwiga ^a   Kazek, Grzegorz ^a   Filipek, Barbara ^a   Librowski, Tadeusz ^b   Wieckowski, Krzysztof ^b   Solnica, Bogdan ^b  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Cytotoxicity; Dihydrofuran 2 one; Glucose utilization; Glutathione; Lipid accumulation

Indexed keywords

1,1 DIPHENYL 2 PICRYLHYDRAZYL; 3 [4 (3 TRIFLUOROMETHYL PHENYL)PIPERAZIN 1 YL] DIHYDROFURAN 2 ONE; ANALGESIC AGENT; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; QUERCETIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; ROSIGLITAZONE; TERFENADINE; TROLOX C; UNCLASSIFIED DRUG; 3-(4-(3-TRIFLUOROMETHYLPHENYL)PIPERAZIN-1-YL)DIHYDROFURAN-2-ONE; 3-VINYLPYRROLE; ANTIOXIDANT; GAMMA BUTYROLACTONE; GLUCOSE; PIPERAZINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN HOMOGENATE; BRAIN TISSUE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DIABETIC NEUROPATHY; DPPH RADICAL SCAVENGING ASSAY; DRUG CYTOTOXICITY; DRUG EFFECT; ENZYME BLOOD LEVEL; EX VIVO STUDY; GLUCOSE UTILIZATION; IN VITRO STUDY; LIPID METABOLISM; LIPID STORAGE; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PAIN THRESHOLD; PRIORITY JOURNAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; ANALOGS AND DERIVATIVES; ANIMAL; CELL LINE; DRUG EFFECTS; HUMAN; METABOLISM;

4-BUTYROLACTONE; ANALGESICS; ANIMALS; ANTIOXIDANTS; CELL LINE; GLUCOSE; GLUTATHIONE; HUMANS; LIPID METABOLISM; MALE; MICE; PIPERAZINES; PYRROLES;

EID: 84896817450     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.3109/15376516.2013.879973     Document Type: Article

References (32)

1. Abou-Seif MA, Youssef AA. (2004). Evaluation of some biochemical changes in diabetic patients. Clin Chim Acta 346:161-70.
2. Arezzo JC, Rosenstock J, Lamoreaux L, Pauer L. (2008). Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: A double-blind placebo-controlled trial. BMC Neurol 8:33.
3. Beutler E, Duron O, Kelly BM. (1963). Improvement method for the determination of blood glutathione. J Lab Clin Med 61:882-8.
4. Bai H, Liu R, Chen HL, et al. (2013). Enhanced antioxidant effect of caffeic acid phenethyl ester and Trolox in combination against radiation induced-oxidative stress. Chem Biol Interact 6:7-15.
5. Bril V. (2012). Treatments for diabetic neuropathy. J Peripher Nerv Syst 17:22-7.
6. Chong MS, Hester J. (2007). Diabetic painful neuropathy: Current and future treatment options. Drugs 67:569-85.
7. Derlacz RA, Hyc K, Usarek M, et al. (2008). PPAR-gamma-independent inhibitory effect of rosiglitazone on glucose synthesis in primary cultured rabbit kidney-cortex tubules. Biochem Cell Biol 86:396-404.
8. Goldberg DM, Spooner RJ. (1983). Assay of glutathione reductase. In: Bergmeyen HV, ed. Methods of enzymatic analysis. Deerfield Beach (FL): Verlag Chemie, 258-65.
9. Hamid R, Rotshteyn Y, Rabadi L, et al. (2004). Comparison of alamar blue and MTT assays for high through-put screening. Toxicol In Vitro 18:703-10.
10. Kumawat M, Sharma TK, Singh I, et al. (2013). Antioxidant enzymes and lipid peroxidation in type 2 diabetes mellitus patients with and without nephropathy. N Am J Med Sci 5:213-19.
11. Kuritzky L. (2010). Managing diabetic peripheral neuropathic pain in primary care. J Fam Pract 59:S15-22.
12. Li YY, Wu HS, Tang L, et al. (2007). The potential insulin sensitizing and glucose lowering effects of a novel indole derivative in vitro and in vivo. Pharmacol Res 56:335-43.
13. Maritim AC, Sanders RA, Watkins 3rd JB. (2003). Diabetes, oxidative stress, and antioxidants: A review. J Biochem Mol Toxicol 17:24-38.
14. Mukherjee R, Hoener PA, Jow L, et al. (2000). A selective peroxisome proliferator-Activated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes. Mol Endocrinol 14:1425-33.
15. Paglia D, Valentine W. (1967). Studies on quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 70:158-65.
16. Pal P, Kanaujiya JK, Lochab S, et al. (2013). Proteomic analysis of rosiglitazone and guggulsterone treated 3T3-L1 preadipocytes. Mol Cell Biochem 376:81-93.
17. Pluijms W, Huygen F, Cheng J, et al. (2011). Evidence-based interventional pain medicine according to clinical diagnoses. 18. Painful diabetic polyneuropathy. Pain Pract 11:191-8.
18. Poitout V, Robertson RP. (2008). Glucolipotoxicity: Fuel excess and betacell dysfunction. Endocr Rev 29:351-66.
19. Salat K, Filipek B, Wieckowski K, Malawska B. (2009). Analgesic activity of 3-mono-substituted derivatives of dihydrofuran-2-one in experimental rodent models of pain. Pharmacol Rep 61:807-18.
20. Salat K, Gawlik K, Witalis J, et al. (2013). Evaluation of antinociceptive and antioxidant properties of 3-[4-(3-Trifluoromethyl-phenyl)- piperazin-1-yl]-dihydrofuran-2-one in mice. Naunyn Schmiedebergs Arch Pharmacol 386:493-505.
21. Salat K, Librowski T, Nawiesniak B, Gluch-Lutwin M. (2013). Evaluation of analgesic, antioxidant, cytotoxic and metabolic effects of pregabalin for the use in neuropathic pain. Neurol Res. 35:948-58.
22. Salat K, Moniczewski A, Salat R, et al. (2012). Analgesic, anticonvulsant and antioxidant activities of 3-[4-(3-Trifluoromethyl-phenyl)-piperazin-1-yl]- dihydrofuran-2-one dihydrochloride in mice. Pharmacol Biochem Behav 101:138-47.
23. Salat R, Salat K. (2013). The application of support vector regression for prediction of the antiallodynic effect of drug combinations in the mouse model of streptozocin-induced diabetic neuropathy. Comput Methods Programs Biomed 111:330-7.
24. Satoh J, Yagihashi S, Baba M, et al. (2011). Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: A 14 week, randomized, double-blind, placebocontrolled trial. Diabet Med 28:109-16.
25. Sharma S, Kulkarni SK, Agrewala JN, Chopra K. (2006). Curcumin attenuates thermal hyperalgesia in a diabetic mouse model of neuropathic pain. Eur J Pharmacol 536:256-61.
26. Takazawa T, Yamauchi T, Tsuchida A, et al. (2009). Peroxisome proliferator-Activated receptor gamma agonist rosiglitazone increases expression of very low density lipoprotein receptor gene in adipocytes. J Biol Chem 284:30049-57.
27. Tesfaye S, Selvarajah D. (2012). Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev 28:8-14.
28. Várkonyi T, Kempler P. (2008). Diabetic neuropathy: New strategies for treatment. Diabetes Obes Metab 10:99-108.
29. Vinik A. (2005). Clinical review: Use of antiepileptic drugs in the treatment of chronic painful diabetic neuropathy. J Clin Endocrinol Metab 90:4936-45.
30. Zhang M, Swarts SG, Yin L, et al. (2011). Antioxidant properties of quercetin. Adv Exp Med Biol 701:283-9.
31. Ziegler D. (2008). Painful diabetic neuropathy: Treatment and future aspects. Diabetes Metab Res Rev 24:S52-7.
32. Zilliox L, Russell JW. (2011). Treatment of diabetic sensory polyneuropathy. Curr Treat Options Neurol 13:143-59.